Ignite Creation Date:
2025-12-26 @ 10:43 PM
Ignite Modification Date:
2025-12-30 @ 5:15 PM
Study NCT ID:
NCT05336812
Status:
RECRUITING
Last Update Posted:
2025-06-03
First Post:
2022-03-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization: